Navigation Links
AACR news: Studies show increasing evidence that androgen drives breast cancer
Date:4/10/2013

Estrogen and progesterone receptors, and the gene HER2 these are the big three markers and/or targets in breast cancer. Evidence presented at the AACR Annual Meeting 2013 adds a fourth: androgen receptors.

"This is a continuing line of work with all evidence pointing toward the addition of the androgen receptor as potential target and useful marker in all of the major subtypes of breast cancer," says Jennifer Richer, PhD, investigator at the University of Colorado Cancer Center and co-director of the CU Cancer Center Tissue Processing and Procurement Core.

The finding of androgen receptors (AR) as a potential target in breast cancer is especially important in light of its prevalence in breast cancers that don't express other hormone receptor targets or have developed resistance to treatments that target estrogen dependence. Overall, approximately 77 percent of breast cancers are positive for AR, including 88 percent of cancers that are estrogen receptor positive, 59 percent of those that are HER2 positive, and 20-32 percent of triple negative breast cancers.

The study presented this week explores the ability of estrogen-positive (ER+) breast cancers to develop resistance to anti-estrogen drugs by potentially developing an alternative addiction to AR and hypothesizes that anti-androgen therapy, such as the drug enzalutamide (formerly MDV3100) as successful counters to breast cancers' evolution. First, Richer and colleagues used breast cancer tumor registries to discover that cancers with higher ratios of AR to ER protein had shorter time to relapse after anti-estrogen therapies. Cut off from their estrogen addition, these cancers may have turned to growth and survival via androgens instead.

The group then returned to the lab to explore the effects of anti-androgen therapies in cell lines and preclinical models.

"Remarkably, the anti-androgen drug enzalutamide had effects comparable to the anti-estrogen drug tamoxifen in breast cancer cells that expressed both ER and AR," Richer says. HER2 cell lines that were also AR+ showed promising responses as well.

"We are excited to move toward clinical trials of anti-androgen therapies in breast cancer," Richer says. "And this study shows that patients with a high AR/ER ratio who relapse while on estrogen targeting therapies might be good candidates for this kind of therapy."


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
805-559-2023
University of Colorado Denver
Source:Eurekalert

Related biology news :

1. Good news: Fewer maternal and child deaths
2. REACH news: European ombudsman takes up PETA complaint
3. AACR news: Paragazole excels in preclinical models of triple-negative breast cancer
4. AACR news: Six2 homeoprotein allows breast cancer cells to detach and metastasize
5. AACR news: Little molecule makes big difference in bladder cancer metastasis
6. AACR news: New target plus new drug equals death of melanoma cells
7. AACR news: K9 osteosarcoma samples identify drivers of metastasis in pediatric bone cancer
8. AACR news: Misregulated genes common to tobacco-related cancers offer potential new prognostic tool
9. Studies reveal structure of EV71, a virus causing childhood illnesses
10. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
11. Autism Speaks awards $1.1 million to fund high priority studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... June 2, 2016   The Weather Company , an ... Ads, an industry-first capability in which consumers will be able ... to ask questions via voice or text and receive relevant ... Marketers have long sought an advertising solution ... can be personal, relevant and valuable; and can scale across ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... WI (PRWEB) , ... June 23, 2016 , ... ... supplements, is pleased to announce the launch of their brand, UP4™ Probiotics, into ... for over 35 years, is proud to add Target to its list of ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
(Date:6/23/2016)... June 23, 2016  The Prostate Cancer Foundation (PCF) is pleased ... and faster cures for prostate cancer. Members of the Class of 2016 were ... Read More About the Class of 2016 PCF Young ... ... ...
Breaking Biology Technology: